Clinical Insights into MicroRNAs in Depression: Bridging Molecular Discoveries and Therapeutic Potential

Abstract

Depression is a major contributor to the overall global burden of disease. The discovery of biomarkers for diagnosis or prediction of treatment responses and as therapeutic agents is a current priority. Previous studies have demonstrated the importance of short RNA molecules in the etiology of depression. The most extensively researched of these are microRNAs, a major component of cellular gene regulation and function. MicroRNAs function in a temporal and tissue-specific manner to regulate and modify the post-transcriptional expression of target mRNAs. They can also be shuttled as cargo of extracellular vesicles between the brain and the blood, thus informing about relevant mechanisms in the CNS through the periphery. In fact, studies have already shown that microRNAs identified peripherally are dysregulated in the pathological phenotypes seen in depression. Our article aims to review the existing evidence on microRNA dysregulation in depression and to summarize and evaluate the growing body of evidence for the use of microRNAs as a target for diagnostics and RNA-based therapies.

BDNF Modulation by microRNAs: An Update on the Experimental Evidence

“…They can be expressed within the activation of a gene promoter or their own promoters [1,2], and play a regulatory role in protein synthesis by targeting and degrading RNA transcripts containing compatible nucleotide sequences [3][4][5][6][7]. MicroRNAs are seen to participate in the functional regulation at the distant synaptic sites in neuronal cells, and to modulate inflammatory mechanisms that lead to neurological diseases [8,9].…”